
Superpower peptides available for pre-order. Get first access.

Peptide science
What is VK2735?
VK2735 is an investigational dual GLP-1/GIP peptide. See VENTURE weight-loss results, VANQUISH and SUNRISE Phase 3 status, and why it is not FDA-approved.
Quick answer
VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP receptor agonist and is not FDA-approved. In the 13-week VENTURE Phase 2 trial of 176 adults, weekly injections lowered mean body weight 9.1% to 14.7%, versus 1.7% with placebo. Two Phase 3 VANQUISH injection trials, of about 4,500 and 1,000 adults, are expected to finish in 2027. Phase 3 SUNRISE tablet trials have been initiated. Access is limited to clinical trials.
- Published
- April 18, 2026
- Last updated
- November 12, 2026
Key takeaways
- Regulatory Status: As of November 2026, VK2735 is not FDA-approved and is in Phase 3 clinical trials1
- Research Stage: Phase 2 complete, VANQUISH injection trials underway, and SUNRISE tablet trials initiated1
- Availability: Clinical trial enrollment2 only, and Superpower does not offer VK2735
- Prescribing information: The VENTURE trial registration3, in place of an FDA label
- How it works: VK2735 activates both the GLP-1 and GIP receptors4
- What the research shows: In VENTURE, weekly 2.5-15 mg injections lowered mean weight 9.1-14.7%4 over 13 weeks in 176 adults with obesity or overweight, vs 1.7% on placebo
Where VK2735 comes from and how it works
VK2735 is an investigational synthetic peptide from Viking Therapeutics, not FDA-approved, that activates receptors for two gut hormones4: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Tirzepatide uses the same dual-receptor approach5.
A side chain on the peptide extends VK2735's half-life4, allowing weekly injections, and Viking is also developing a daily tablet1.
GLP-1 raises insulin after meals, slows stomach emptying, and reduces food intake6. GIP was the first incretin hormone identified7. Drugs pairing GLP-1 activation with either activating or blocking the GIP receptor8 have produced similar weight loss in clinical studies. Why both GIP strategies work is unsettled. MariTide blocks the GIP receptor9, while VK2735's human trials test activation.
What the human evidence shows
In the 13-week VENTURE Phase 2 trial, mean body weight fell 9.1% to 14.7% across doses4, versus 1.7% with placebo. The 176 adults had obesity, or overweight with at least one weight-related condition, and took weekly VK2735 injections of 2.5 to 15 mg.
Phase 2 trials like VENTURE are not large enough to confirm benefit10, the job of Phase 3.
VENTURE results at week 13, adults without diabetes:
| Arm | Mean weight change at week 13 | Reached at least 5% weight loss |
| Placebo | −1.7% | 11.5% |
| VK2735 2.5 mg | −9.1% | 80.8% |
| VK2735 5 mg | −10.9% | 97% |
| VK2735 10 mg | −12.9% | 93.8% |
| VK2735 15 mg | −14.7%4 | 100% |
The VK2735 tablet has company-reported Phase 2 results, with no peer-reviewed paper yet. In the 13-week VENTURE-Oral trial of 280 adults11 with obesity or overweight, daily 120 mg tablets lowered mean weight 12.2%12, versus 1.3% with placebo. Of people on VK2735, 28% stopped treatment12, versus 18% on placebo.
Weight returned after people stopped tirzepatide13. An exploratory, company-reported Viking study therefore tested less frequent VK2735 dosing. After 21 weeks of weekly injections, adults with obesity lost a mean 16.3% to 18.7%14 of body weight, versus 0.1% with placebo. Those moved to dosing every other week or monthly for 12 weeks kept an average of 90% and 85%14 of that loss, versus 61% on placebo. Each maintenance group held 10 to 16 people.
Registered Phase 2 and Phase 3 VK2735 trials of the injection and the tablet:
| Trial | Formulation | Phase | Population | Duration | Status |
| VENTURE3 | Weekly injection, 2.5-15 mg | 2 | 176 adults with obesity or overweight, no diabetes | 13 weeks | Completed; results peer reviewed |
| VENTURE-Oral11 | Daily tablet, 15-120 mg | 2 | 280 adults with obesity or overweight | 13 weeks | Completed August 2025; company-reported results only |
| VANQUISH-115 | Weekly injection, 7.5-17.5 mg | 3 | About 4,500 adults with obesity or overweight, without type 2 diabetes | 78 weeks | Active, not recruiting; completion expected 2027 |
| VANQUISH-216 | Weekly injection, 7.5-17.5 mg | 3 | About 1,000 adults1 with obesity or overweight and type 2 diabetes | 78 weeks | Active, not recruiting; completion expected 2027 |
| SUNRISE-12 | Daily tablet, 27.5-55 mg | 3 | 560 adults planned, without type 2 diabetes | 68 weeks | Initiated |
| SUNRISE-217 | Daily tablet, 27.5-55 mg | 3 | 560 adults planned, with type 2 diabetes | 68 weeks | Initiated |
VK2735's regulatory path now depends on what these Phase 3 trials show.
Regulatory status
As of November 2026, VK2735 is an investigational drug18, not FDA-approved for any use, and cannot be prescribed outside a clinical trial.
Outside trials, the FDA's expanded access pathway19 is limited to serious or immediately life-threatening conditions with no comparable alternative.
VK2735 has no compounding pathway, since VK2735 meets none of the FDA conditions for compounding from bulk substances20. Viking expects the VANQUISH trials to finish in 20271. Approval would then need a New Drug Application and FDA review21, steps that approved GLP-1 drugs have already cleared.
How VK2735 compares with other GLP-1 drugs
VK2735 shares the dual mechanism of tirzepatide, an FDA-approved GIP and GLP-1 receptor agonist22, but no trial has measured how VK2735 compares with tirzepatide.
This comparison is for scientific context only, since the drugs differ in regulatory status and evidence base, and separate trials cannot be compared reliably.
GLP-1 receptor agonists such as semaglutide, CagriSema, retatrutide, and the oral pill orforglipron set the context for VK2735's side effects.
Safety: what is and is not known
VK2735's most common side effects in VENTURE were nausea, vomiting, diarrhea, and constipation4. Peer-reviewed VK2735 safety data end at 13 weeks.
Digestive effects are common across GLP-1-based drugs23 and often ease with slow dose increases24, as they did in VENTURE. Still, 9.1% of VENTURE participants stopped treatment4 for an adverse event. The 78-week VANQUISH-2 trial is tracking pancreatitis, gallbladder, and cardiovascular events25.
The FDA has not found investigational drugs safe and effective19, so VK2735 use belongs in trials tracking VK2735 side effects over time.
The bottom line
VK2735 is Viking Therapeutics' investigational peptide targeting GLP-1 and GIP receptors. Phase 2 trials showed dose-related weight loss4, Phase 3 injection trials are expected to finish in 20271, tablet trials have been initiated, and VK2735 remains unapproved.
Where can I learn about peptides?
Investigational drugs like VK2735 generate both peer-reviewed papers and company announcements, and the two deserve different weight. Superpower’s peptide library lays that evidence out plainly, with each article written and fact-checked by a team of health journalists and licensed clinicians.
For how a single peptide can act on two hormone receptors, read up on the science behind peptides.
IMPORTANT SAFETY INFORMATION
VK2735 is an investigational drug currently under clinical development by Viking Therapeutics. It has not been approved by the FDA, or any other regulatory authority, for any medical use. Because VK2735 is not FDA-approved, does not appear on the FDA's 503A bulk drug substances list, and is not a component of any approved drug, it is not lawfully available through compounding pharmacies in the United States. VK2735 is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.
No boxed warning exists for VK2735 as no approved labeling has been issued. Class-level GLP-1 receptor agonist labeling for approved agents includes a warning regarding thyroid C-cell tumors based on rodent studies; a causal relationship in humans has not been established. Whether this class-level signal applies to VK2735 has not been established.
VK2735 should not be used by anyone outside the VK2735 clinical trial program; there is no approved indication and no contraindication table because there is no approved use. Populations of particular theoretical concern based on class-level mechanisms (not established from VK2735-specific data) include: personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2); known hypersensitivity to VK2735 or its excipients; pregnancy or breastfeeding (safety not established).
Warnings (class-level, not VK2735-specific): gastrointestinal adverse events including nausea, vomiting, diarrhea, and constipation; pancreatitis risk (class consideration; causal relationship in humans not established); gastroparesis exacerbation; lean mass loss with prolonged weight reduction therapy.
Common side effects reported in VENTURE Phase 2 trial: nausea, vomiting, diarrhea, constipation. Most were mild to moderate and decreased after dose titration. Long-term safety data have not been published.
Full safety information will be available in FDA-approved prescribing information upon approval, if granted. Until that time, VK2735 should not be used outside of authorized clinical trial enrollment.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to VK2735. VK2735 is an investigational compound that is not FDA-approved; access is limited to clinical trial enrollment. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.